Earnings Miss: Jamjoom Pharmaceuticals Factory Company Missed EPS By 5.1% And Analysts Are Revising Their Forecasts

Shareholders might have noticed that Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) filed its yearly result this time last week. The early response was not positive, with shares down 9.1% to ر.س158 in the past week. It looks like the results were a bit of a negative overall. While revenues of ر.س1.3b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 5.1% to hit ر.س5.10 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Jamjoom Pharmaceuticals Factory after the latest results.

Check out our latest analysis for Jamjoom Pharmaceuticals Factory

Taking into account the latest results, the current consensus from Jamjoom Pharmaceuticals Factory's five analysts is for revenues of ر.س1.52b in 2025. This would reflect a solid 15% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to ascend 15% to ر.س5.87. In the lead-up to this report, the analysts had been modelling revenues of ر.س1.50b and earnings per share (EPS) of ر.س5.91 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

There were no changes to revenue or earnings estimates or the price target of ر.س178, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Jamjoom Pharmaceuticals Factory, with the most bullish analyst valuing it at ر.س187 and the most bearish at ر.س165 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Jamjoom Pharmaceuticals Factory'shistorical trends, as the 15% annualised revenue growth to the end of 2025 is roughly in line with the 13% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 9.4% per year. So it's pretty clear that Jamjoom Pharmaceuticals Factory is forecast to grow substantially faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Jamjoom Pharmaceuticals Factory going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for Jamjoom Pharmaceuticals Factory that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.